{
    "clinical_study": {
        "@rank": "55480", 
        "arm_group": [
            {
                "arm_group_label": "B:  No induction", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses."
            }, 
            {
                "arm_group_label": "A:  Induction", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to test the efficacy of using standard immune therapy for melanoma prior to\n      stereotactic radiosurgery (ipilimumab induction), as compared to stereotactic radiosurgery\n      followed by immune therapy. The study's hypothesis is that  ipilimumab induction is as good\n      as or better than controlling brain metastases as compared to stereotactic radiosurgery\n      followed by immune therapy."
        }, 
        "brief_title": "Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery", 
        "condition": [
            "Metastatic Melanoma", 
            "Brain Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized Phase II selection study investigating the use of ipilimumab induction\n      prior to stereotactic radiosurgery (SRS), versus no induction, for melanoma brain\n      metastases. Participants will be randomized to Arm A \"Induction\" (two doses of  ipilimumab\n      prior to SRS, two doses of ipilimumab after SRS)  versus Arm B \"No induction\" (SRS first,\n      followed by 4 doses of ipilimumab). Participants will undergo multiple dynamic\n      contrast-enhanced MRIs of the brain and submit blood samples for immune testing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a histologically-confirmed diagnosis of melanoma who have imaging\n             findings suggestive of 1 to 4 brain metastases\n\n          -  At least one lesion in the brain that is measurable, which is defined as \u22655 x 5mm\n             (Prior craniotomy and surgical resection is allowed, as long as there is at least one\n             remaining measurable lesion in the brain)\n\n          -  Patients must be candidates for stereotactic radiosurgery (SRS) and planning to\n             undergo SRS\n\n          -  Patients must be candidates for ipilimumab as determined by the treating physician\n\n          -  Patients must be neurologically asymptomatic, or very minimally symptomatic, as\n             judged by the treating physicians\n\n          -  At least 3 weeks has elapsed from any prior therapy, and the patient has recovered\n             from side effects to \u2264 grade 1 toxicities per  Common Terminology Criteria (CTC) for\n             Adverse Events\n\n          -  Age > or = 18 years old\n\n          -  Performance status of ECOG of 0 or 1 (ECOG is the Eastern Oncology Cooperative Group\n             Scoring system used to quantify cancer patients' general well-being and activities of\n             daily life; scores range from 0 to 5 where 0 is perfect health and 5 is death)\n\n          -  Adequate organ and marrow function:  alanine aminotransferase (ALT ) < 2.5x's upper\n             limit of normal (ULN) of the institutional normal reference range, aspartate\n             aminotransferase (AST) < 2.5x's ULN of the institutional normal reference range,\n             Bilirubin < 1.5x's ULN of the institutional normal reference range, Creatinine < 2.0\n             milligrams per deciliter, Platelets > 50,000 per microliter\n\n          -  Women of child-bearing potential must agree to use adequate contraception, defined as\n             complete abstinence from intercourse with men or two methods\n\n          -  Ability to understand and the willingness to sign a written informed consent\n\n        Exclusion Criteria:\n\n          -  Previous radiotherapy to the lesion(s) of interest, including prior treatment with\n             whole brain radiation therapy (WBRT). Prior treatment with SRS is allowed if the\n             index lesion(s) is in a different, non-contiguous location than the previously\n             treated lesion.\n\n          -  Patients who have previously received ipilimumab, PD-1 inhibitors or PD-L1 inhibitors\n             are excluded due to the potential of effects on primary outcome\n\n          -  Patients who require WBRT or surgery at the time of enrollment\n\n          -  Neurologic symptoms or imaging findings that necessitate the use of steroids on the\n             day of enrollment or in the prior 7 days\n\n          -  Highly suspicious magnetic resonance imaging (MRI) or cerebrospinal fluid evidence of\n             leptomeningeal metastases, unless all measurable disease is localized and SRS is\n             considered the treatment of choice\n\n          -  Concurrent treatment with any other anti-neoplastic drug or concurrent participation\n             in another therapeutic clinical trial\n\n          -  Patients unable to undergo or tolerate MRI scans (presence of cardiac pacemaker,\n             implanted cardiac defibrillator, aneurysm clips, history of allergic\n             reaction/hypersensitivity to gadolinium)\n\n          -  Women who are pregnant or are nursing\n\n          -  Patients with absolute lymphocyte count of <500 cells/microliter, who are known to be\n             HIV positive, who have clinically significant active autoimmune disease, or are\n             receiving immunosuppression following solid organ or stem cell transplant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097732", 
            "org_study_id": "UMCC 2013.114", 
            "secondary_id": "HUM00082134"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "B:  No induction", 
                    "A:  Induction"
                ], 
                "description": "Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "B:  No induction", 
                    "A:  Induction"
                ], 
                "description": "Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.", 
                "intervention_name": "Stereotactic Radiosurgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Metastatic melanoma", 
            "Brain metastases", 
            "Radiation therapy", 
            "Immune therapy"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "silka@umich.edu", 
                "last_name": "Ann Silk, M.D.", 
                "phone": "734-647-8906"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Ann Silk, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christopher Lao, M.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery", 
        "other_outcome": [
            {
                "description": "Exploratory endpoints: Interval changes in dynamic MRI parameters such as perfusion, blood volume, vascular permeability (Ktrans), and diffusion tensor imaging; the change in 3D tumor volume.", 
                "measure": "Imaging correlates on dynamic-contrast enhanced MRI of the brain", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Exploratory endpoints:  Interval changes in immune markers in the blood", 
                "measure": "Immune correlates", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "silka@umich.edu", 
            "last_name": "Ann Silk, M.D.", 
            "phone": "734-647-8906"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Cancer Center", 
            "last_name": "Christopher Lao, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients in each arm who are free from progression in the index (radiated) lesions in the brain at 6 months.", 
            "measure": "Local control rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097732"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan Cancer Center", 
            "investigator_full_name": "Christopher Lao", 
            "investigator_title": "Clinical Assistant Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Toxicities will be tabulated by grade separately by treatment arm. For each arm, the highest grade of a given toxicity within each patient will be counted, and rates of toxicity will be calculated with 95% exact confidence intervals", 
                "measure": "Toxicity Rate", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Overall Survival Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 months"
            }, 
            {
                "description": "The proportion of patients in each arm who are free from progression in the index (radiated) lesions and free from new brain metastases at 6 months.", 
                "measure": "Regional (intracranial) control rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Response of treated (irradiated) brain metastases to combination therapy with ipilimumab and stereotactic radiosurgery using immune-related response criteria.", 
                "measure": "Intracranial response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "Time to progression in the brain due to treated metatases or new brain metastases.", 
                "measure": "Time to event data", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 months"
            }
        ], 
        "source": "University of Michigan Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Christopher Lao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}